Role of medical advances in population longevity improvement. A case study on statins.

Lisanne Gitsels, Elena Kulinskaya, Nicholas Steel and Nigel Wright

University of East Anglia and Aviva plc
About the speaker

- **Elena Kulinskaya**
  - Professor, Aviva Chair in Statistics
  - MSc (Maths) Moscow
  - PhD (Stats) Vilnius

- **University of East Anglia**
  - Research Grant on the Use Of Big Health And Actuarial Data For Understanding Longevity And Morbidity Risks by the Consortium of UEA and Aviva Life Plc funded by the IFoA Actuarial Research Centre 2016-2020
Disclaimer: The views expressed in this presentation are those of invited contributors and not necessarily those of the Institute and Faculty of Actuaries. The Institute and Faculty of Actuaries do not endorse any of the views stated, nor any claims or representations made in this presentation and accept no responsibility or liability to any person for loss or damage suffered as a consequence of their placing reliance upon any view, claim or representation made in this presentation. The information and expressions of opinion contained in this publication are not intended to be a comprehensive study, nor to provide actuarial advice or advice of any nature and should not be treated as a substitute for specific advice concerning individual situations. On no account may any part of this presentation be reproduced without the written permission of the Institute and Faculty of Actuaries.
Quantifying longevity changes

- Medical advances are the major drivers in the longevity increase. But how to quantify this relationship?

- Our research uses The Health Improvement Network (THIN) primary care data, to develop statistical models of longevity.

- The advantage of using individual-level medical data is that it is possible to model both the uptake of medical treatment and the effect of that treatment on longevity conditional on the individual sociodemographic and health factors instead of the aggregated profile.
Recent changes in mortality improvements

“From 1968-2010, 70% of all mortality improvements can be attributed to the fall in deaths from circulatory diseases.

... The period 2011-16 saw much lower mortality improvements in circulatory diseases.”

Jon Palin on behalf of the CMI Mortality Projections Committee, Mortality improvements in decline The Actuary, 2017/08
Drivers of these changes

- But what were the drivers of this rapid improvement and the consequent decline in longevity improvement rates?

- We show that these developments in longevity are mainly due to statins, cholesterol lowering drugs prescribed to prevent cardiovascular disease (CVD).
Data

- The Health Improvement Network (THIN) data
  - Medical records from primary care
  - Representative of the UK when adjusted for deprivation
- All patients born before 1960 and followed to 01.01.2017, this includes 3.5 million patients
- Added various social economic status variables such as Townsend score, IMD and Mosaic
New Guidelines on Primary prevention of CVD

Primary prevention: no previous history of CVD
- Example: lipid-lowering therapy - statins

National Institute of Health and Clinical Excellence (NICE):
- Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10% or greater 10-year risk of developing CVD.
- Estimate the level of risk using the QRISK2 assessment tool
- www.nice.org.uk/guidance/cg181/
- www.qrisk.org/2016/

Up to 17 million UK residents eligible for statins
Design and Data Selection

- Population-based retrospective cohort study
- Restrictions data:
  - Medical records from 1987 to 2011 of people born between 1920 and 1940
- Target ages:
  - 60, 65, 70, and 75 [between 115,000-250,000 patients, 52-58% women]
- Exclusion:
  - Patients with a history of cardiovascular disease


QRISK groups by age over time
Hazard ratios of mortality with statins

Cox regression with frailty on GP practice. HRs adjusted for sex, year of birth, deprivation, diabetes, high cholesterol, blood pressure regulating drugs, body mass index, smoking status

<table>
<thead>
<tr>
<th>QRISK2 at baseline</th>
<th>Statins Deaths (%per annum)</th>
<th>No LLT Deaths (%per annum)</th>
<th>Adjusted HR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 60</td>
<td>43 (0.59)</td>
<td>5,027 (0.68)</td>
<td>1.20 (0.87–1.67)</td>
</tr>
<tr>
<td>Age 65</td>
<td>41 (0.59)</td>
<td>2,899 (0.71)</td>
<td>0.97 (0.71–1.34)</td>
</tr>
<tr>
<td>10–19%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 60</td>
<td>124 (1.19)</td>
<td>8,921 (1.42)</td>
<td>1.12 (0.92–1.36)</td>
</tr>
<tr>
<td>Age 65</td>
<td>470 (0.94)</td>
<td>17,187 (1.52)</td>
<td>1.01 (0.91–1.11)</td>
</tr>
<tr>
<td>Age 70</td>
<td>486 (0.94)</td>
<td>14,639 (1.67)</td>
<td>0.89 (0.81–0.99)</td>
</tr>
<tr>
<td>Age 75</td>
<td>30 (1.35)</td>
<td>1,618 (1.76)</td>
<td>0.79 (0.52–1.19)</td>
</tr>
<tr>
<td>&gt;=20%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 60</td>
<td>52 (1.99)</td>
<td>1,012 (2.50)</td>
<td>1.02 (0.76–1.36)</td>
</tr>
<tr>
<td>Age 65</td>
<td>663 (1.79)</td>
<td>7,348 (2.89)</td>
<td>0.86 (0.79–0.94)</td>
</tr>
<tr>
<td>Age 70</td>
<td>2,142 (1.93)</td>
<td>23,070 (3.16)</td>
<td>0.83 (0.79–0.88)</td>
</tr>
<tr>
<td>Age 75</td>
<td>3,094 (2.53)</td>
<td>32,279 (3.61)</td>
<td>0.82 (0.79–0.86)</td>
</tr>
</tbody>
</table>
What does this mean for longevity

- Using Gompertz law, the increase in annual hazard of mortality associated with ageing one year is approximately constant between ages 30 and 95.
- For England and Wales in 2010-2012, the increase in the hazard between those ages was approximately 1.1.
- A HR can be translated to the numbers of years gained in effective age as \[ \log \text{HR}/ \log (1.1) \approx 10 \times \log(\text{HR}). \]  
  [Brenner, 1993; Spiegelhalter, 2016]
Translating to population life expectancy

- Take a period life table
- Calculate effective age changes due to a health intervention in relevant subpopulations [risk group, age, sex and deprivation status]
- The longevity improvement associated with statin prescription translates to a decrease in effective age of up to two years
- Take into account uptake rates in these subgroups
- Population LE is the weighted average of the LE in these subgroups
Prevalence of statins prescription for primary prevention of cardiovascular disease by deprivation quintiles (Townsend)

Statins prescription in people with QRISK2≥20%*

*summarised over 1995-2011
Impact of Recent changes in Guidelines: the increase in overall life expectancy (yrs) if all eligible people were prescribed statins

<table>
<thead>
<tr>
<th>Townsend deprivation quintile</th>
<th>Age 70</th>
<th>Age 75</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Women</td>
<td>Men</td>
</tr>
<tr>
<td>1st (least)</td>
<td>0.74-0.76</td>
<td>0.82-0.84</td>
</tr>
<tr>
<td>2nd</td>
<td>0.75-0.76</td>
<td>0.82-0.85</td>
</tr>
<tr>
<td>3rd</td>
<td>0.74-0.76</td>
<td>0.81-0.84</td>
</tr>
<tr>
<td>4th</td>
<td>0.70-0.72</td>
<td>0.77-0.80</td>
</tr>
<tr>
<td>5th (most)</td>
<td>0.62-0.65</td>
<td>0.80-0.83</td>
</tr>
<tr>
<td>Total</td>
<td>0.73-0.75</td>
<td>0.81-0.84</td>
</tr>
</tbody>
</table>
Statins prescription rate by age-risk group

Statin prescription in patients with QRISK2 score < 20%

Statin prescription in patients with QRISK2 score ≥ 20%

Statin prescription in patients with CVD

Age 60 | Age 65 | Age 70 | Age 75

1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011

100% 80% 60% 40% 20% 0%

100% 80% 60% 40% 20% 0%

100% 80% 60% 40% 20% 0%
Statins prescription rate by age-risk group

High-Risk Patients

Low- and Moderate-Risk Patients
How much statins have already contributed to the increase in current LE?

The LE of 1987, when statins were introduced to the healthcare market, was compared to the LE of 2010 as it is and as if there was no statin prescription.

The increase in LE from 1987 to 2010 in women was 2.7 and 2.2 years at ages 70 and 75, and in men 3.7 and 2.8 years at ages 70 and 75.

Statins contributed to 74% (60-89%) of this increase in LE at age 70 and to 57% (45-71%) of this increase at age 75.
Conclusions

- Longevity improvement due to statins is already in part incorporated in the national LE due to the 90% prescription rate in CVD survivors.

- Our results agree amazingly well with the conclusions by the CMI. However, the national LE would further increase by up to one year if all eligible people under the current guidelines would be prescribed statins.

- Methodology is easily applied to future health interventions such as newly recommended by the American Heart Association (2017) intensive blood pressure control.
Thank you very much for your attention!

Contact details:

**Elena Kulinskaya**

address: School of Computing Sciences, University of East Anglia
NR4 7TJ Norwich UK

phone: +44 (0)1603/592-692

mail: e.kulinskaya@uea.ac.uk

web: www.bighealthactuarialdata.ac.uk